Lesson 7 - Starting Medication

1. Introduction

Why This Topic Matters

Starting ADHD medication is a clinically important transition point. Up to this stage, the clinician has assessed the patient, established the diagnosis, explained ADHD, discussed treatment options and selected an appropriate medication.

The next question is:

"How do we start treatment safely and in a way that gives us useful information?"

This is more than simply writing the first prescription.

The way medication is started influences:

• patient confidence

• adherence

• interpretation of benefit

• recognition of adverse effects

• titration decisions

• safety monitoring

• the quality of future prescribing decisions

A poorly planned start can create confusion very quickly.

If the patient does not understand what the medication is for, when to take it, what to expect, which adverse effects matter or when review will occur, it becomes difficult to know whether subsequent problems reflect the medication itself, incorrect use, unrealistic expectations or inadequate monitoring.

By contrast, a well-structured initiation provides a clear baseline and a clear plan.

Starting Medication Begins Before the First Dose

Before medication is started, several things should already be in place.

The clinician should be satisfied that:

• the ADHD diagnosis is sufficiently established

• medication is clinically indicated

• the selected treatment is appropriate for the patient

• relevant physical and psychiatric history has been reviewed

• baseline observations have been completed where required

• current medication and potential interactions have been considered

• relevant cardiovascular issues have been assessed

• misuse or diversion risk has been considered where appropriate

• treatment goals have been identified

• the patient understands the proposed treatment

Starting medication safely therefore depends on good work having been completed beforehand.

The first prescription should be the beginning of a planned treatment trial, not an isolated prescribing event.

Define What Success Will Look Like

Before the first dose is taken, identify what the medication is intended to improve.

Avoid vague goals such as:

"Improve concentration."

Use more specific targets.

For example:

• complete classroom work more consistently

• interrupt less frequently

• reduce careless mistakes

• follow conversations more effectively

• meet work deadlines

• complete household tasks

• manage morning routines with fewer prompts

These functional targets make later titration much more meaningful.

If you do not know what you are trying to improve, you will struggle to determine whether treatment is working.

Establish the Baseline

A useful principle is:

Measure before you change.

Before medication begins, document the current picture.

This may include:

• symptom severity

• areas of functional impairment

• pulse

• blood pressure

• weight

• height and growth where appropriate

• appetite

• sleep

• mood

• anxiety

• tics

• relevant behavioural difficulties

• substance use

• current risk

This creates a reference point.

If the patient later reports insomnia, appetite loss, irritability or palpitations, you need to know whether these were present before treatment.

Without a baseline, adverse-effect interpretation becomes much more difficult.

Explain the Medication Clearly

Patients should understand:

what they are taking

why this medication has been selected

how and when to take it

what benefit might reasonably be expected

which adverse effects are common

which symptoms require earlier review

what monitoring is required

when the next review will occur

The level of detail should be appropriate to the medication.

For stimulant treatment, the patient may be able to notice changes relatively quickly.

For a gradual-onset non-stimulant such as Atomoxetine, expectations need to be different.

Starting treatment is therefore partly an exercise in expectation-setting.

Avoid Promising a Dramatic Effect

Some patients expect the first dose to transform their functioning.

Others are anxious that they will immediately feel overstimulated or become a different person.

A balanced explanation is more helpful.

For example:

"The aim is not for you to feel medicated. We are looking for meaningful improvements in attention, impulse control and day-to-day functioning while keeping adverse effects acceptable."

This gives the patient a realistic framework for judging response.

Start Low, Then Learn From the Response

Medication initiation is usually followed by titration.

The first dose is not necessarily intended to be the final therapeutic dose.

Starting cautiously allows the clinician to assess:

• tolerability

• early benefit

• adverse effects

• physical response

• adherence

Treatment can then be adjusted according to what actually happens.

The principle is:

start appropriately, observe carefully, then optimise.

Not:

start and hope.

Safety-Netting Is Part of Prescribing

Patients should know what to do if something concerning occurs.

The exact advice depends on the medication, but may include seeking earlier clinical review for symptoms such as:

• significant cardiovascular symptoms

• marked mental-state deterioration

• severe behavioural change

• syncope

• severe adverse effects

• significant allergic symptoms

• new suicidal thinking where relevant

The clinician should also explain what to do if:

• doses are missed

• medication is accidentally taken incorrectly

• prescriptions are lost

• treatment is interrupted

• another medication is started

This is particularly important with controlled drugs and with medications that should not be stopped abruptly.

Starting Medication Is a Shared Decision

The patient should not feel that treatment is simply being done to them.

Before prescribing, confirm that they understand the plan and are willing to proceed.

A useful final question is:

"What are your main concerns about starting this medication?"

This may reveal worries about:

• dependence

• appetite

• sleep

• personality change

• stigma

• long-term treatment

• driving

• school or work

• previous adverse experiences

Addressing these concerns before the first dose can improve both adherence and the quality of future review.

How This Fits Into the Overall Course

The previous lessons have taken the learner through:

diagnostic assessment

↓

diagnostic formulation

↓

explaining the diagnosis

↓

psychoeducation

↓

non-pharmacological management

↓

stimulant medication

↓

non-stimulant medication

↓

choosing the right medication

We now move from selection to initiation.

The clinical question is no longer:

"Which medication should we use?"

It is:

"How do we begin this treatment safely, clearly and in a way that allows us to evaluate it properly?"

This lesson will therefore focus on:

• pre-treatment assessment

• baseline physical and psychiatric review

• informed discussion and consent

• defining treatment targets

• starting doses

• practical administration

• early adverse effects

• safety-netting

• adherence

• controlled-drug considerations

• patient and family education

• planning the first review

• what information should be documented at initiation

The central principle is:

Starting ADHD medication should be a structured clinical process, not simply the issuing of a prescription.

A good start creates the conditions for good titration, good monitoring and better long-term treatment decisions.

2. Learning Outcomes

By the end of this lesson, learners should be able to:

1. Complete an appropriate pre-treatment assessment before starting ADHD medication, including review of physical health, cardiovascular history, mental state, current medication, relevant comorbidity, substance use and baseline observations.

2. Define clear treatment targets and baseline measures, identifying the specific symptoms and areas of functional impairment that should improve if medication is effective.

3. Explain a medication initiation plan clearly to patients and families, including why the medication has been selected, how and when it should be taken, what early effects to expect and which adverse effects or warning symptoms require review.

4. Start ADHD medication safely and appropriately, understanding the principles of cautious initiation, initial dosing, adherence, medication-specific administration and the difference between a starting dose and an optimised therapeutic dose.

5. Provide effective safety-netting and early monitoring, including advice about missed doses, treatment interruptions, controlled-drug issues where relevant, significant adverse effects and when urgent or earlier clinical assessment may be required.

6. Plan and document the first medication review, recording the rationale for treatment, baseline findings, agreed functional targets, monitoring requirements and the information needed to guide subsequent titration.

3. The Lecture

Starting Medication Is a Clinical Intervention, Not a Prescription

When we talk about "starting medication", it is easy to imagine that the important event is the prescription.

It is not.

The important event is the structured initiation of a therapeutic trial.

By the time you prescribe the first dose, you should already know:

why you are treating

what you are treating

what you are going to measure

what risks you have considered

what the patient should expect

and

what you will do next.

If those things are unclear, the prescription is premature.

A useful way of thinking about initiation is:

Baseline → Treatment targets → Medication education → Starting dose → Early observation → Titration → Review

Each stage generates information that informs the next.

Before the First Prescription

NICE recommends a full baseline assessment before starting ADHD medication.

This is not simply a physical-health checklist. It is an opportunity to make sure that the proposed treatment remains appropriate after bringing together the diagnostic formulation, current clinical state and medication plan.

The baseline assessment should consider:

• confirmation that the patient continues to meet criteria for ADHD and requires treatment

• mental-health and social circumstances

• relevant psychiatric comorbidity

• current educational or occupational circumstances

• risk of substance misuse and medication diversion

• current medication

• physical health

• height and weight where appropriate

• baseline pulse and blood pressure

• cardiovascular assessment

The exact requirements vary according to age, medication and individual clinical circumstances.

The underlying principle is simple:

Do not expose someone to a treatment before establishing the information you will later need to judge its safety and effectiveness.

The Pre-treatment Consultation

Imagine a 26-year-old who has completed an ADHD assessment and returns saying:

"Great. Can I start Lisdexamfetamine today?"

There is a temptation to move directly to the prescription.

Instead, structure the consultation.

You need to establish:

1. Is medication still appropriate?

2. Has anything changed since the assessment?

3. Are baseline observations available?

4. Is there anything in the cardiovascular history requiring further assessment?

5. What medication and substances is the patient currently taking?

6. What are the agreed treatment targets?

7. Does the patient understand the proposed medication?

8. What is the starting and titration plan?

9. What monitoring is required?

10. When will treatment be reviewed?

That is medication initiation.

Confirm That Nothing Important Has Changed

There may be a gap between assessment and prescribing.

Ask whether there have been changes in:

• physical health

• mental state

• medication

• substance use

• pregnancy status where relevant

• cardiovascular symptoms

• appetite or weight

• sleep

• risk

• social circumstances

A medication decision made several months ago should not simply be implemented without considering what has happened since.

This is particularly important where the patient has developed:

• significant depression

• mania

• psychosis

• escalating substance misuse

• severe eating difficulties

• significant cardiovascular symptoms

• new interacting medication

The appropriate response may be to proceed, modify the plan, investigate further or temporarily defer ADHD medication.

Establish the Physical Baseline

Pulse and Blood Pressure

Pulse and blood pressure should be recorded before treatment.

The value of this is not merely deciding whether medication can be started.

It also gives you a baseline against which subsequent changes can be interpreted.

If a patient's pulse is 96 beats per minute before treatment and 100 after treatment, that means something very different from a rise from 62 to 100.

The same principle applies to blood pressure.

Always interpret observations in context rather than treating them as isolated numbers.

Height and Weight

For children and young people, height and weight provide an important baseline because growth and weight trajectory may subsequently be relevant.

In adults, weight should also be recorded.

Do not merely record:

"Weight normal."

Record an actual measurement.

If appetite suppression subsequently occurs, you need objective information with which to compare it.

Cardiovascular Assessment

Cardiovascular safety often creates disproportionate anxiety around ADHD prescribing.

The answer is neither to ignore cardiovascular history nor to investigate every patient excessively.

The correct approach is targeted cardiovascular assessment.

Ask about:

• known congenital or acquired cardiac disease

• previous cardiac surgery

• exertional syncope

• unexplained fainting

• exertional breathlessness

• significant palpitations

• cardiac-type chest pain

• known hypertension

• relevant family history, particularly premature sudden cardiac death suggestive of inherited cardiac disease

Examine and investigate further where clinically indicated.

The purpose is to identify the minority of patients who require additional assessment before medication is started.

Does Everyone Need an ECG?

No.

A routine ECG is not required for every person before starting ADHD medication when the history and examination do not identify an indication for one.

This is an important practical point because unnecessary investigations can delay effective treatment and create anxiety without improving clinical care.

An ECG may, however, be indicated when the cardiovascular history, examination, coexisting condition or concomitant medication raises a relevant concern.

The principle is:

Investigate according to clinical indication, not simply because ADHD medication is being prescribed.

Review Current Medication

Before prescribing, perform medication reconciliation.

Do not ask only:

"Are you on any psychiatric medication?"

Ask about:

• prescribed medication

• over-the-counter medication

• supplements

• relevant recreational substances

Check potential interactions using an authoritative prescribing source rather than relying on memory.

This becomes particularly important when patients are taking:

• antidepressants

• antihypertensives

• medications affecting heart rate or blood pressure

• medications affecting relevant metabolic pathways

• sedating medication

• other psychotropic medication

A competent prescriber does not need to memorise every possible interaction.

A competent prescriber needs to recognise when an interaction check is required.

Establish the Psychiatric Baseline

Physical observations receive considerable attention before ADHD medication, but the psychiatric baseline is equally important.

Document relevant pre-treatment:

• mood

• anxiety

• irritability

• emotional dysregulation

• sleep

• psychotic symptoms

• manic symptoms

• suicidal thinking

• tics

• substance use

Why?

Because these may subsequently change.

Suppose a patient reports irritability two weeks after starting medication.

Was the irritability new?

Did it exist beforehand?

Did it worsen after treatment?

Does it occur when medication is active?

Does it occur when medication wears off?

Without a baseline, causal interpretation becomes difficult.

Assess Substance Use and Diversion Risk

This should not be approached as an accusation.

Ask routinely and neutrally about:

• alcohol

• cannabis

• cocaine

• amphetamines

• other recreational substances

• previous substance dependence

• previous misuse of prescribed medication

Where stimulant medication is being considered, also think about diversion.

Ask whether anyone else might have access to the medication.

For adolescents and students in particular, consider the environment in which controlled medication will be stored.

A patient can have genuine ADHD and still be vulnerable to:

• misuse

• coercion

• theft

• sharing

• selling medication

Safe prescribing requires us to consider both.

Pregnancy and Reproductive Considerations

For patients who could become pregnant, reproductive circumstances may need to form part of medication initiation.

Ask where clinically relevant about:

• current pregnancy

• possibility of pregnancy

• breastfeeding

• pregnancy plans

The risk-benefit discussion should be individualised according to the medication and circumstances, using current prescribing information and specialist advice where necessary.

Do not assume that every patient will volunteer this information without being asked.

Define the Treatment Targets Before Starting

This is one of the most important parts of medication initiation.

Ask:

"If this treatment works, what should be different in your life?"

Do not settle for:

"I want better concentration."

Make it specific.

For an adult:

"I want to complete a report without repeatedly abandoning it."

"I want to stop missing important details in meetings."

"I want to complete household tasks rather than starting six things at once."

For a child:

"Complete more classroom work."

"Require fewer prompts during the morning routine."

"Interrupt less frequently."

"Remain seated sufficiently to participate in lessons."

These are measurable clinical targets.

Symptoms and Function Are Not the Same Thing

Medication may reduce symptoms without producing sufficient functional improvement.

Equally, a relatively modest symptom change may produce a major functional benefit.

For example, a patient may still describe themselves as distractible but now:

• arrives at work on time

• finishes documentation

• makes fewer mistakes

• drives more safely

• manages household responsibilities

That is clinically meaningful.

Therefore, when treatment starts, establish both:

symptom targets

and

functional targets.

Establish Baseline Rating Measures Where Appropriate

Standardised rating scales can provide useful baseline information and help track change during titration.

In children, information from parents and teachers may be particularly valuable.

In adults, patient-reported measures can contribute useful information.

But rating scales should support clinical judgement rather than replace it.

A score cannot tell you everything about:

• quality of life

• relationships

• driving

• parenting

• occupational functioning

• subjective tolerability

Use measurement to improve clinical reasoning, not to mechanise it.

Explain What the Medication Is Supposed to Do

Patients often begin treatment with unrealistic expectations.

Some expect:

"I'll finally become motivated."

Others:

"My brain will become quiet."

Others:

"I'll suddenly be able to organise my entire life."

Medication may reduce core ADHD symptoms and improve the patient's capacity to function.

It does not automatically:

• create organisational systems

• repair relationships

• eliminate every executive difficulty

• resolve trauma

• cure sleep deprivation

• remove environmental stress

• provide motivation for activities the patient genuinely does not want to do

Explain this before treatment.

Otherwise, genuine therapeutic benefit may be dismissed because the medication has not solved every difficulty associated with years of living with ADHD.

What Should a Patient Expect to Feel?

This is a useful discussion.

Some patients expect to feel medication working dramatically.

That is not necessarily the goal.

A better question is:

"What are you able to do differently?"

Perhaps they notice:

• less internal distractibility

• greater ability to remain with tasks

• reduced impulsivity

• improved conversational attention

• easier task initiation

Sometimes the patient notices little subjectively while family members or colleagues notice substantial behavioural change.

This is why functional observation matters.

Starting Stimulant Medication

Stimulants can produce therapeutic effects relatively quickly, but that does not mean the first dose determines whether the treatment is ultimately successful.

The initial dose is usually a starting point for titration.

Explain this explicitly.

A patient may take the first dose and report:

"Nothing happened."

That does not necessarily mean the medication has failed.

The starting dose may deliberately be conservative.

The correct response is not for the patient to increase the medication independently.

It is to follow the agreed titration plan.

Starting Non-stimulant Medication

Expectations need to be different with non-stimulants.

A patient beginning Atomoxetine should not expect the same rapid assessment of effect that might occur with a stimulant.

Therapeutic benefit develops more gradually.

This means adherence becomes particularly important.

If the patient takes medication inconsistently for a short period and concludes that it has not worked, the trial may be uninterpretable.

Explain the expected time course before treatment starts.

Start Low – But Do Not Stay Low Without a Reason

"Start low and go slow" is useful advice, but it can be misunderstood.

Starting cautiously does not mean leaving a patient indefinitely on a subtherapeutic dose because everyone is nervous about increasing it.

Titration has a purpose:

to identify the dose that produces the best balance of benefit and tolerability.

You therefore need a plan for:

• starting dose

• dose increments

• interval between changes

• monitoring

• review

• circumstances in which titration should pause

Use the current BNF, BNF for Children and product-specific SmPC for exact dosing instructions.

Do not prescribe doses from memory when authoritative information is available.

Titrate Against Response, Not Against the Dose Range

Suppose a patient starts treatment and improves substantially at a relatively modest dose.

Do you automatically continue increasing because the BNF allows a higher dose?

No.

Now imagine another patient tolerates the starting dose perfectly but experiences minimal benefit.

Do you conclude the medication has failed?

Again, no.

Dose optimisation requires balancing:

ADHD symptom reduction

functional improvement

against

adverse effects.

The dose range tells you what may be prescribed.

It does not tell you which dose is right for this patient.

Slower Titration in More Complex Patients

Some patients warrant more cautious titration and closer monitoring.

Examples include people with:

• autism

• tic disorders

• learning disability

• significant anxiety

• depression

• bipolar disorder

• psychotic illness

• eating disorders

• post-traumatic stress disorder

• substance misuse

• cardiac disease

• epilepsy

• acquired brain injury

This does not mean these patients cannot receive ADHD medication.

It means the margin for careless prescribing is smaller.

NICE specifically recommends slower titration and more frequent monitoring where relevant neurodevelopmental, mental-health or physical-health conditions are present.

Practical Administration Matters

Never assume that:

"Take one every morning"

is sufficient counselling.

Different preparations may have specific administration requirements.

Depending on the medication and formulation, you may need to discuss:

• timing

• relationship to food

• whether tablets or capsules must be swallowed whole

• whether a particular capsule can be opened

• what to do if a dose is forgotten

• what to do if medication is taken late

• storage

• school administration

• travel

These instructions are product-specific.

Check the current SmPC.

Food Can Matter

This is particularly relevant with some modified-release Methylphenidate preparations.

Different long-acting Methylphenidate products have different release mechanisms and administration requirements, including differences relating to food.

Do not assume that all modified-release Methylphenidate preparations can be taken in exactly the same way.

This is one reason the specific product matters.

Modified-Release Methylphenidate: Know What You Prescribed

Long-acting Methylphenidate products are not pharmacologically identical simply because the label contains the same active ingredient.

They differ in:

• immediate-release proportion

• modified-release proportion

• release mechanism

• pharmacokinetic profile

• duration

• food requirements

The MHRA has specifically advised caution when switching between long-acting Methylphenidate preparations because differences in formulation and instructions for use can alter both symptom control and adverse effects.

When starting one, document the specific preparation clearly and explain how it should be taken.

Think About Breakfast

This is a surprisingly practical prescribing point.

A child or adult who already struggles to eat may experience additional appetite suppression once stimulant medication becomes active.

Where appropriate, encourage a good breakfast before the medication's appetite effect becomes established.

More importantly, document the patient's baseline eating pattern.

If someone already skips breakfast and lunch before medication, subsequent poor daytime intake cannot automatically be attributed entirely to treatment.

Again:

baseline first, interpretation second.

Sleep Before Stimulants

Ask about baseline sleep before starting treatment.

Document:

• bedtime

• sleep-onset latency

• waking

• sleep duration

• daytime sleepiness

• caffeine use

• delayed sleep pattern

Then if insomnia develops, you can ask:

"What has actually changed?"

Medication-related sleep disturbance may sometimes be addressed through:

• timing

• dose

• formulation

• treatment of a pre-existing sleep problem

Do not immediately prescribe another medication to treat insomnia without understanding the mechanism.

Caffeine and Other Stimulants

Patients sometimes start stimulant medication while continuing very high caffeine intake.

Then they report:

• tremor

• palpitations

• anxiety

• restlessness

• insomnia

Ask about:

• coffee

• tea

• energy drinks

• pre-workout products

• caffeine tablets

This does not mean everyone must stop caffeine completely.

It means you need to understand the total stimulant burden when interpreting adverse effects.

Controlled Drugs: Explain the Practicalities

Many stimulant ADHD medications are controlled drugs.

Patients should understand that this has practical implications.

Discuss:

• safe storage

• not sharing medication

• keeping medication away from children and others

• prescription arrangements

• what to do if medication is lost or stolen

• travel considerations where relevant

For adolescents and university students, secure storage can be particularly important.

A student living in shared accommodation should not leave stimulant medication somewhere easily accessible to others.

Never Share Medication

This sounds obvious, but it should be said explicitly.

Patients may encounter friends who say:

"Can I try one? I think I've got ADHD too."

Explain that medication should never be:

• shared

• sold

• exchanged

• given to another person

Apart from legal considerations, the other person has not undergone the necessary clinical assessment.

Explain Common Adverse Effects Before They Happen

Patients tolerate expected adverse effects differently from unexplained adverse effects.

Before starting treatment, discuss the common and clinically important effects relevant to the chosen medication.

For stimulants this may include:

• reduced appetite

• weight change

• sleep disturbance

• headache

• gastrointestinal symptoms

• increased pulse or blood pressure

• subjective overstimulation

• mood or behavioural changes

For Atomoxetine, discussion may include:

• gastrointestinal symptoms

• appetite effects

• sleepiness or insomnia

• cardiovascular effects

• sexual adverse effects in adults

• relevant mood and safety warnings

For Guanfacine, discussion may include:

• sedation

• fatigue

• dizziness

• hypotension

• bradycardia

The discussion should be proportionate.

The aim is informed treatment, not frightening the patient with an unstructured recital of every adverse event ever reported.

Distinguish Common Effects From Red Flags

Patients should know which symptoms can reasonably wait until routine review and which require earlier assessment.

For example, mild appetite reduction is different from:

• syncope

• significant cardiac symptoms

• severe behavioural change

• emerging psychotic or manic symptoms

• serious allergic reaction

• significant suicidal thinking

• other severe or rapidly worsening adverse effects

The exact safety-netting should reflect the medication and individual patient.

Give patients a clear route for obtaining help.

What About Emotional Blunting?

Patients sometimes describe:

"I don't feel like myself."

or:

"I feel emotionally flat."

Take this seriously.

Do not respond:

"But your concentration is better."

A medication can improve ADHD symptoms and still be unacceptable to the patient.

Clarify what they mean.

Is this:

• emotional blunting?

• excessive dose?

• anxiety?

• dysphoria?

• rebound?

• fatigue?

• reduced impulsive emotional expression that feels unfamiliar?

The subjective experience matters.

The aim is improved functioning without making the patient feel that treatment has removed something important about themselves.

Early Irritability: Timing Matters

If irritability appears after starting a stimulant, ask:

When does it occur?

Irritability while medication is at peak effect may mean something different from irritability as medication wears off.

Also ask whether irritability was present before treatment.

Timing can distinguish:

• adverse effect

• excessive dose

• rebound

• baseline emotional dysregulation

• unrelated stress

Never interpret an adverse effect without understanding its temporal relationship to medication.

Do Not Treat Every Adverse Effect With Another Drug

This is a common route into unnecessary polypharmacy.

A patient develops insomnia.

A hypnotic is added.

Appetite falls.

Another intervention is added.

Blood pressure rises.

Another medication is considered.

Before adding treatment to manage treatment, ask:

"Is the original ADHD medication still the right medication, dose and formulation?"

Sometimes adjunctive treatment is appropriate.

But sometimes the most elegant intervention is to correct the original prescription.

The First Few Days: What Should the Patient Observe?

Encourage patients to observe rather than continuously monitor themselves anxiously.

Useful questions include:

Can I stay with tasks more easily?

Am I less distractible?

Am I interrupting less?

Can I begin tasks more readily?

Can I complete them?

When does benefit begin?

When does it wear off?

What happens to appetite?

What happens to sleep?

Do I feel physically or emotionally different?

This gives clinically useful information for titration.

Collateral Information Can Be Extremely Helpful

Children may not recognise their own response accurately.

Parents and teachers can provide valuable observations.

Adults may also benefit from collateral observations from a partner or family member where appropriate and with consent.

For example:

"I don't think it's doing anything."

Partner:

"You haven't interrupted me once during dinner this week, and you've arrived home with everything you went to work with."

Neither perspective should automatically override the other.

Together, they improve the assessment.

Do Not Judge Treatment by Productivity Alone

There is a danger of turning ADHD medication into a productivity intervention.

Treatment success should not simply mean:

more work completed.

Consider:

• emotional regulation

• relationships

• driving

• self-care

• daily routines

• cognitive fatigue

• impulsivity

• quality of life

• ability to disengage from work appropriately

A patient who becomes intensely productive for twelve hours but stops eating, sleeping and interacting with their family is not necessarily optimally treated.

Clinical Example 1: The Adult Starting Lisdexamfetamine

A 34-year-old accountant with ADHD has significant occupational and home impairment.

Baseline assessment identifies:

• normal blood pressure and pulse

• no significant cardiovascular history

• stable weight

• longstanding mild sleep-onset difficulty

• no substance misuse

• no significant current psychiatric instability

Treatment targets are:

1. completing financial reports without repeatedly abandoning them

2. reducing impulsive interruptions in meetings

3. improving completion of evening household tasks

You explain that the starting dose is part of titration rather than necessarily the final dose.

You discuss:

• administration

• appetite

• sleep

• cardiovascular monitoring

• controlled-drug storage

• expected response

• when to seek earlier review

At follow-up, the patient reports:

"My concentration is definitely better, but I'm sleeping worse."

Because baseline sleep was documented, you can now determine whether there has been a genuine change.

That is the value of structured initiation.

Clinical Example 2: The Child Starting Methylphenidate

An 8-year-old with significant combined-presentation ADHD is starting Methylphenidate.

Before treatment you record:

• height

• weight

• pulse

• blood pressure

• appetite

• sleep

• baseline ADHD symptoms

• school impairment

Parents and school identify treatment targets:

complete more independent classroom work

remain seated sufficiently to participate in lessons

require fewer prompts during morning routines

At review, the teacher reports major improvement in classroom engagement.

Parents report reduced appetite at lunchtime.

Now you have a genuine clinical decision:

How meaningful is the benefit?

How significant is the appetite effect?

What has happened to weight?

Can treatment be optimised without losing benefit?

That is much more informative than asking:

"Is the medication working?"

Clinical Example 3: The Patient Who Takes the First Dose at the Wrong Time

A university student receives a long-acting stimulant and takes the first dose at 2pm because that is when they collect the prescription.

They then cannot sleep.

At review they conclude:

"This medication gives me terrible insomnia."

Perhaps it does.

But first ask:

How was it taken?

Administration errors can mimic medication intolerance.

Clear counselling at initiation prevents avoidable problems.

Clinical Example 4: The Patient Who Feels Nothing

A 30-year-old starts a low dose of stimulant medication.

After three days they send a message:

"I can't feel anything. Can I double it?"

The response should not be:

"Yes, if you feel nothing."

Reinforce the agreed titration schedule.

Explain that subjective sensation is not the therapeutic target.

Ask about:

• attention

• impulsivity

• task completion

• duration

• adverse effects

The patient should not self-titrate outside the agreed plan.

Clinical Example 5: The Patient With Anxiety

A 25-year-old with ADHD and generalised anxiety starts medication.

You already know that anxiety is present at baseline.

During titration they report increased anxiety.

Now ask:

Did anxiety increase immediately after treatment?

Is it dose-related?

Does it correspond to peak medication effect?

Has caffeine use changed?

Has sleep deteriorated?

Has functional anxiety elsewhere actually improved?

Because the baseline was documented, the adverse-effect assessment is considerably more sophisticated than:

"Stimulants cause anxiety, so stop."

The First Review Should Be Planned Before the Patient Leaves

Do not issue medication and say:

"See how you get on."

The patient should know:

• when treatment will be reviewed

• what information to collect

• whether observations are required

• how titration will occur

• who to contact with problems

• what warrants earlier review

Medication initiation without planned follow-up is incomplete prescribing.

What Should You Review During Titration?

At each meaningful stage of titration, consider four domains:

1. Symptoms

What has changed in:

• attention

• hyperactivity

• impulsivity

• executive functioning?

2. Function

What has changed at:

• school

• university

• work

• home

• relationships

• driving?

3. Adverse Effects

What has happened to:

• appetite

• weight

• sleep

• mood

• anxiety

• physical symptoms?

4. Physical Monitoring

What has happened to relevant observations such as:

• pulse

• blood pressure

• weight

• growth where appropriate?

Then ask:

Is the current balance good enough, or should we adjust?

Titration Is an Experiment With One Patient

There is a useful way to conceptualise this.

Every titration is essentially a structured N-of-1 clinical experiment.

You have:

Baseline

↓

Intervention

↓

Observation

↓

Dose adjustment

↓

Further observation

↓

Optimisation

The quality of the experiment depends on the quality of the observations.

If the patient changes doses unpredictably, takes medication inconsistently and cannot describe what happened, interpretation becomes difficult.

This is why the initiation plan matters so much.

When Should You Pause Titration?

Do not continue increasing medication simply because that was the original schedule.

Pause and review when:

• adverse effects become clinically significant

• physical observations become concerning

• mental state deteriorates

• new cardiovascular symptoms occur

• significant weight or appetite problems emerge

• misuse or diversion concerns arise

• adherence is unclear

• the patient has already achieved good therapeutic benefit

A titration schedule is a plan.

It is not an instruction to ignore clinical information.

When Should You Stop and Reassess?

Occasionally the correct decision is not to continue.

Reassess urgently or promptly as appropriate if significant concerns emerge, including:

• serious cardiovascular symptoms

• marked psychiatric deterioration

• psychotic or manic symptoms

• significant suicidality

• serious allergic reaction

• substantial medication misuse

• severe adverse effects

The response will depend on the medication, severity and clinical circumstances.

Use current product information and appropriate specialist or emergency pathways where required.

Documentation at Initiation

A good initiation note should allow another clinician to understand:

Why was medication started?

Why this medication?

What baseline assessment was completed?

What are the treatment targets?

What dose is being started?

What is the titration plan?

What adverse effects were discussed?

What safety-netting was provided?

What monitoring is required?

When is review planned?

For example:

"Following discussion of pharmacological and non-pharmacological options, patient wishes to commence medication for ADHD. Baseline cardiovascular history reviewed with no identified indication for further cardiac investigation. Pulse, blood pressure and weight recorded. Current medication and substance use reviewed. Treatment targets include improved sustained attention during reports, reduced impulsive interruption during meetings and improved completion of evening household tasks. Administration, expected benefits, common and important adverse effects, controlled-drug storage and safety-netting discussed. Agreed titration plan explained. Review arranged to assess efficacy, duration, tolerability and physical observations."

That is a clinically meaningful record.

Common Mistakes When Starting Medication

Several errors recur in practice.

Prescribing before baseline observations are available

You then lose the reference point needed for monitoring.

Giving medication without defining treatment targets

The subsequent review becomes vague.

Failing to explain that the starting dose is a starting dose

The patient concludes prematurely that treatment has failed.

Giving inadequate administration instructions

The patient may take medication at the wrong time or inconsistently.

Ignoring baseline sleep and appetite

Subsequent adverse-effect attribution becomes unreliable.

Allowing unsupervised dose changes

Titration becomes difficult to interpret and potentially unsafe.

Failing to plan follow-up

Treatment drifts without proper optimisation.

Changing several medications simultaneously

You lose the ability to understand what caused benefit or harm.

A Practical Starting-Medication Framework

Before issuing the first prescription, mentally work through the following sequence:

Confirm

Diagnosis → indication → medication choice

Baseline

Physical health → cardiovascular assessment → observations → mental state → medication → substance use

Target

Symptoms → functional impairment → patient priorities

Explain

Medication → administration → expected benefit → adverse effects → safety-netting

Prescribe

Starting dose → formulation → clear instructions

Plan

Titration → monitoring → review → contact arrangements

If one of these elements is missing, ask whether you are genuinely ready to start.

What Good Initiation Sounds Like

A good medication-starting conversation might sound something like this:

"We have agreed that medication is appropriate and that this is the most suitable option to start with. Your baseline physical observations are satisfactory, and I have reviewed your medical history and current medication. We are going to start at a low dose and adjust it according to benefit and adverse effects rather than trying to reach a particular dose.

The main things we are looking for are whether you can stay with tasks more consistently, complete your reports and manage your evening responsibilities more effectively. I would also like you to pay attention to appetite, sleep, mood and any physical symptoms.

Do not change the dose outside the agreed plan. If you develop significant or concerning symptoms, contact us earlier rather than waiting for the routine review. Otherwise, we will review what has changed, how long the medication is helping and whether the current balance between benefit and adverse effects is good enough."

That conversation turns a prescription into a treatment plan.

The Central Clinical Principle

The first prescription should answer four questions:

Is it safe to start?

What are we trying to improve?

What exactly should the patient do?

How will we know what to do next?

If you cannot answer those questions, you are not yet ready to prescribe.

Starting medication well establishes the foundations for everything that follows:

safe titration

meaningful monitoring

accurate interpretation of response

effective shared decision-making

and ultimately

optimised long-term treatment.

The aim is therefore not simply to get medication started.

It is to begin treatment in a way that allows both clinician and patient to learn systematically from what happens next.

4. Clinical Perspective

Starting ADHD medication is often where prescribing quality becomes most visible.

A technically correct prescription can still lead to poor treatment if the patient leaves without understanding what to expect, how to take the medication, what to monitor or when to ask for help.

The most useful clinical mindset is:

Start with a clear baseline.

Make the plan explicit.

Change one thing at a time where possible.

Review what actually happened.

Clinical Pearls

Baseline Information Is What Makes Later Interpretation Possible

Do not underestimate the value of documenting:

• appetite

• sleep

• anxiety

• irritability

• pulse

• blood pressure

• weight

• height where relevant

• tics

• current functioning

before treatment begins.

If the patient later develops insomnia, weight loss or irritability, you need to know whether these are genuinely new or simply more noticeable after treatment starts.

A good baseline turns subsequent adverse-effect assessment from guesswork into clinical reasoning.

Define Success Before You Prescribe

Ask:

"If this medication works, what should be different?"

A patient who answers:

"I want to focus better"

needs help making the goal more concrete.

For example:

• finish reports without repeatedly abandoning them

• complete more classroom work

• miss fewer deadlines

• interrupt less often

• manage evening routines more independently

When treatment targets are clear, titration becomes much easier.

Tell Patients That the Starting Dose Is Not a Test of Whether They "Have ADHD"

Some patients think:

"If I take the first dose and nothing happens, maybe I don't really have ADHD."

Correct this before treatment begins.

Medication response does not establish the diagnosis.

A low starting dose may also produce little therapeutic benefit because the aim is initially to assess tolerability before further titration.

Do Not Aim for a Particular Dose

The correct end point is not:

"We reached 50mg."

It is:

"We reached the dose where meaningful benefit was achieved with acceptable adverse effects."

If that occurs at a lower dose, stop increasing.

Ask What Changed Functionally

At review, avoid relying only on:

"Do you feel different?"

Ask:

"What can you do now that was harder before?"

This may reveal more clinically useful information than subjective sensation.

Practical Tips for Everyday Practice

Use a Simple Starting-Medication Checklist

Before the first prescription, mentally check:

Diagnosis confirmed

Medication indicated

Medication selected appropriately

Baseline physical assessment completed

Current medication reviewed

Substance-use risk considered

Treatment targets agreed

Administration explained

Adverse effects discussed

Safety-netting provided

Follow-up planned

If one of these is missing, ask whether prescribing should proceed yet.

Ask the Patient to Repeat the Plan Back

A useful question is:

"Just so I know I've explained it clearly, can you tell me how you're going to take it?"

This can uncover misunderstandings immediately.

For example:

• taking a long-acting stimulant late in the afternoon

• doubling the dose if the first day feels ineffective

• taking Atomoxetine only on workdays

• planning to stop Guanfacine suddenly

Teach-back is particularly useful when medication instructions are complex.

Write Down the Titration Plan Clearly

Do not assume the patient will remember verbal instructions.

Where appropriate, provide clear written instructions covering:

• starting dose

• when to increase

• what not to change without advice

• when review will occur

• what symptoms require earlier contact

This reduces avoidable dosing errors.

Ask About Real-Life Administration

For children:

• Who gives the medication?

• Is school administration required?

• Is there a reliable morning routine?

For adults:

• What time do they wake?

• Do they work shifts?

• Do they skip breakfast?

• Do they travel frequently?

• Will they remember a second dose?

A theoretically ideal regimen can be clinically poor if it does not fit the patient's routine.

Make the First Review Easy to Interpret

Ask the patient to observe only the things that matter.

For example:

Benefit

• attention

• impulsivity

• task completion

• duration

Tolerability

• appetite

• sleep

• mood

• physical symptoms

Too much self-monitoring can create anxiety and produce unhelpful noise.

Common Pitfalls and Misconceptions

"The First Dose Should Tell Us Whether It Works"

Not necessarily.

This is particularly misleading with gradual-onset non-stimulants, but even stimulant starting doses may be deliberately conservative.

"No Side Effects Means Increase"

Not automatically.

Dose increases should be driven by insufficient benefit, not simply by the absence of adverse effects.

"Some Benefit Means Keep Increasing"

Again, not automatically.

If the patient already has meaningful functional improvement with good tolerability, further dose escalation may add little.

"A Normal ECG Is Required Before Every Stimulant"

Not routinely.

Further cardiovascular investigation should be based on clinical indication rather than habit.

"A Mild Adverse Effect Means Stop Immediately"

Not necessarily.

Assess:

• severity

• timing

• persistence

• functional impact

• dose relationship

Some mild effects may settle or be manageable.

"A Recognised Side Effect Can Be Ignored"

Also incorrect.

Recognised adverse effects still require clinical assessment.

"Starting Medication Means Non-pharmacological Treatment Is No Longer Needed"

Medication may improve symptoms but does not automatically solve organisational, environmental or psychological difficulties.

Treatment remains multimodal where indicated.

Advice for Newly Qualified Doctors

Know What You Are Prescribing

Before issuing the prescription, know:

• formulation

• starting dose

• administration instructions

• expected duration where relevant

• important adverse effects

• monitoring requirements

• titration plan

If unsure, check the BNF, BNF for Children or SmPC.

Do not guess.

Do Not Let the Clinic Run Faster Than Your Clinical Reasoning

Medication-start appointments can feel routine.

They should not become automatic.

Pause if:

• observations are abnormal

• the cardiovascular history is unclear

• the patient has started new medication

• mental state has changed

• pregnancy is relevant

• substance misuse has escalated

• the proposed treatment no longer fits the current formulation

A brief delay to clarify a safety issue is better than starting treatment blindly.

Document Why You Started the Medication

A good note should make the decision understandable to another clinician.

Record:

• rationale

• baseline

• targets

• dose

• titration plan

• monitoring

• counselling

• safety-netting

• follow-up

Do Not Encourage Self-Titration

Patients should not:

• double doses

• skip between strengths unpredictably

• restart after long interruptions without advice

• change timing substantially

• combine preparations

outside the agreed plan.

Unstructured dose changes make both safety and response interpretation more difficult.

Situations Requiring Particular Clinical Judgement

Significant Cardiovascular History

If there is:

• exertional syncope

• unexplained fainting

• cardiac-type chest pain

• significant palpitations

• known structural heart disease

• concerning family history

do not treat initiation as routine.

Further assessment may be needed before starting medication.

Current Mania or Psychosis

Routine ADHD initiation should generally not proceed as though nothing else is happening.

The acute psychiatric presentation takes priority and specialist input may be required.

Significant Eating Difficulties or Low Weight

Treatment may still be possible, but appetite and weight require particular attention.

Establish:

• nutritional baseline

• current intake

• weight trajectory

• eating-disorder symptoms where relevant

The risk-benefit discussion may need to be more cautious.

Significant Substance Misuse or Diversion Risk

Clarify:

• current use

• stability

• previous misuse of prescriptions

• diversion risk

• storage arrangements

• formulation

• monitoring

The presence of ADHD does not remove these risks.

Complex Polypharmacy

If the patient is taking multiple psychotropic or cardiovascular medications, check interactions before starting ADHD treatment.

This is especially important when the proposed medication may affect:

• blood pressure

• heart rate

• metabolism of other drugs

• sedation

• mental state

Patient Is Extremely Anxious About Starting

Do not dismiss this.

Explore what they fear.

Some worries may be based on misinformation.

Others may reflect previous medication experiences.

Clear explanation and a cautious plan often improve engagement.

Patient Wants Immediate Escalation

A patient may say:

"My friend is on 50mg. Can I just start there?"

Explain that dose is individual.

The objective is not to match someone else's prescription.

It is to identify the safest and most effective dose for them.

A Useful First-Review Structure

At the first medication review, ask:

1. What are you actually taking?

Confirm dose, preparation, timing and adherence.

2. What has improved?

Symptoms and functioning.

3. When does it work?

Relevant particularly to stimulants.

4. What adverse effects have occurred?

Appetite, sleep, mood, physical symptoms and medication-specific concerns.

5. What do the observations show?

Pulse, blood pressure, weight and growth where relevant.

6. Is the current plan still appropriate?

Continue, increase, reduce, change, pause or investigate.

Final Clinical Message

Starting ADHD medication well is mostly about creating clarity.

Clarity about:

why treatment is being started

what success should look like

what the patient should take

what they should monitor

what requires concern

when the next decision will be made

The first prescription is not the end of the decision.

It is the beginning of a structured treatment experiment.

If initiation is done well, subsequent titration becomes safer, adverse effects are easier to interpret and treatment decisions become much more defensible.

The central principle is:

Do not simply start medication. Start a clear, measurable and safely monitored treatment plan.

5. Summary

Starting ADHD medication should be understood as the beginning of a structured therapeutic trial, not simply the issuing of a prescription.

Before treatment begins, the clinician should confirm that the diagnosis is established, medication is indicated, the selected treatment remains appropriate and no important clinical circumstances have changed since the original assessment.

A careful baseline assessment is essential. This should include relevant physical and psychiatric history, current medication, substance use, cardiovascular assessment and appropriate physical observations such as pulse, blood pressure, weight and height where relevant.

Baseline information is important because it provides the reference point against which later treatment effects and adverse effects can be interpreted.

Before prescribing, define what successful treatment should look like. Treatment targets should be specific and functionally meaningful rather than vague.

Examples include:

• completing classroom work more consistently

• missing fewer work deadlines

• interrupting less frequently

• managing routines with fewer prompts

• completing administrative tasks more reliably

• functioning more effectively at home

Medication should be evaluated against both symptom change and functional improvement.

The patient should understand why the medication has been selected, how and when to take it, what benefits might reasonably be expected, which adverse effects are important and when earlier review is required.

Expectation-setting is particularly important.

A stimulant starting dose may not represent the final therapeutic dose, and a lack of immediate benefit does not automatically indicate treatment failure.

With gradual-onset non-stimulants such as Atomoxetine, patients should understand that meaningful improvement may take considerably longer to become apparent.

Titration should be cautious but purposeful. The objective is not to reach the highest available dose. It is to identify the dose and formulation that produce the best balance between:

symptom improvement

functional benefit

tolerability

and

safety.

Patients should not change the dose independently outside the agreed titration plan.

Practical administration also matters. Different formulations may have specific requirements regarding timing, food, swallowing, missed doses and storage. Product-specific prescribing information should therefore be checked rather than assuming that all preparations can be used in the same way.

Particular care is required with modified-release Methylphenidate products because different preparations can have different release characteristics and administration requirements.

Common and clinically important adverse effects should be discussed before treatment starts. These may include changes in appetite, weight, sleep, mood, cardiovascular symptoms, gastrointestinal symptoms, sedation or other medication-specific effects.

Safety-netting is an essential component of initiation. Patients and families should know what to do if significant or unexpected symptoms occur, how to obtain help and when not to wait until the routine review.

Controlled-drug considerations should also be discussed where relevant, including safe storage, not sharing medication, lost prescriptions and diversion risk.

Follow-up should be planned before the patient leaves. At review, clinicians should assess:

what medication was actually taken

what symptoms improved

what changed functionally

when benefit occurs and how long it lasts

what adverse effects emerged

what physical observations show

and

whether the current plan should continue or change.

Titration should pause if significant adverse effects, concerning physical observations, mental-state deterioration, cardiovascular symptoms, misuse concerns or unclear adherence make continuation unsafe or difficult to interpret.

Some patients require slower titration and closer monitoring because of significant psychiatric, neurodevelopmental or physical comorbidity.

Good documentation should record:

• why medication was started

• why the specific medication was selected

• baseline findings

• agreed treatment targets

• starting dose and formulation

• titration plan

• adverse-effect counselling

• safety-netting

• monitoring requirements

• planned review

The central principle is:

Do not simply start medication. Start a clear, measurable and safely monitored treatment plan.

A well-planned initiation makes subsequent titration safer, helps clinicians interpret benefit and adverse effects more accurately and creates a stronger foundation for long-term ADHD treatment.

6. Further Reading

The following resources are recommended for consolidating the practical principles involved in starting ADHD medication safely and effectively.

The most useful reading for this lesson focuses on four areas:

pre-treatment assessment

safe prescribing

dose titration

and

monitoring treatment response and adverse effects.

NICE Guidance

National Institute for Health and Care Excellence

Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87)

This is the essential starting point for clinicians practising in the UK.

For this lesson, particular attention should be given to the sections covering:

• baseline assessment before medication

• cardiovascular assessment

• medication considerations before prescribing

• dose titration

• monitoring treatment effectiveness

• monitoring adverse effects

• weight and growth

• cardiovascular monitoring

• sleep

• behavioural changes

• medication review

NICE recommends that an appropriate baseline assessment is completed before ADHD medication is started. This includes relevant physical-health assessment, current medication, height and weight where appropriate, baseline pulse and blood pressure, cardiovascular assessment and consideration of mental-health and social circumstances.

The guidance is also useful in correcting the misconception that every patient requires an ECG before starting stimulant medication. Routine ECG assessment is not required where cardiovascular history and examination do not indicate a need for it, although further investigation may be necessary where relevant clinical concerns are identified.

During titration, NICE recommends recording ADHD symptoms, impairment and adverse effects at baseline and following dose changes, with regular specialist review.

Dose should be titrated against both therapeutic response and adverse effects until optimisation is achieved.

The important concept is that optimisation means more than symptom reduction. It includes improvement in areas such as education, employment, relationships and behaviour while adverse effects remain tolerable.

NICE also recommends slower titration and more frequent monitoring where relevant neurodevelopmental, mental-health or physical-health conditions are present.

Recommended reading: NICE NG87, particularly the sections on baseline assessment, medication, dose titration and monitoring.

British National Formulary and BNF for Children

BNF and BNFC

The British National Formulary and BNF for Children should be used alongside NICE whenever ADHD medication is initiated.

These are practical prescribing resources rather than background reading.

Before starting a medication, clinicians should use the appropriate formulary to confirm:

• licensed indications

• starting dose

• titration schedule

• maximum recommended dose

• contraindications

• cautions

• interactions

• adverse effects

• monitoring requirements

A particularly important habit for doctors learning ADHD prescribing is:

Do not rely on remembered doses when an authoritative prescribing reference is readily available.

Medication doses, licensing arrangements and product availability can change.

Summary of Product Characteristics

Electronic Medicines Compendium

The current Summary of Product Characteristics (SmPC) should be consulted for the specific preparation being prescribed.

This becomes particularly important when questions arise about:

• administration with food

• whether capsules can be opened

• whether tablets must be swallowed whole

• missed doses

• treatment interruption

• discontinuation

• interactions

• contraindications

• uncommon but important adverse effects

• use in particular patient groups

This is especially relevant for modified-release Methylphenidate because products containing the same active ingredient can have different release profiles and administration requirements.

A useful prescribing principle is:

Know the drug, but also know the preparation.

Canadian ADHD Practice Guidelines

Canadian ADHD Resource Alliance (CADDRA)

Canadian ADHD Practice Guidelines, 4.1 Edition

The CADDRA guidelines are particularly useful for clinicians learning how to move from medication selection into practical titration.

Their titration guidance emphasises establishing a schedule for contact with the patient and family, identifying specific treatment targets and using information from relevant observers, such as teachers, where appropriate.

CADDRA describes the general principle of starting cautiously and continuing titration until treatment goals are achieved, adverse effects prevent further increases or the relevant dose ceiling is reached.

Importantly, the guideline defines optimal treatment in functional as well as symptomatic terms.

This complements the NICE approach particularly well.

Useful sections include:

• pharmacological treatment

• treatment targets

• medication initiation

• titration

• monitoring

• adverse effects

• ongoing follow-up

The guideline also provides practical tools for recording baseline symptoms and following medication response.

CADDRA additionally maintains a medication chart covering practical characteristics such as starting doses, titration and duration of action. The chart was updated in 2026, although clinicians in the UK should continue to use UK licensing information and the BNF/BNFC for actual prescribing decisions.

Australian Evidence-Based Clinical Practice Guideline for ADHD

Australian ADHD Professionals Association

Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder

This guideline provides a useful international perspective on pharmacological management across children, adolescents and adults.

It is particularly helpful for understanding:

• individualised medication treatment

• shared decision-making

• titration

• monitoring

• management of adverse effects

• medication in the presence of comorbidity

• integration of medication with non-pharmacological management

It complements NICE well because it provides additional clinical discussion around how treatment recommendations can be translated into individual patient decisions.

For UK clinicians, NICE, BNF/BNFC and UK product information should remain the primary sources for actual prescribing decisions.

Landmark Comparative Medication Evidence

Cortese et al. (2018)

Cortese S, Adamo N, Del Giovane C, et al.

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.

The Lancet Psychiatry. 2018;5(9):727–738.

This remains an important paper for understanding the evidence underpinning pharmacological ADHD treatment.

The network meta-analysis included 133 double-blind randomised controlled trials and examined both efficacy and tolerability across children, adolescents and adults.

The study is useful for this lesson because it reinforces a fundamental prescribing principle:

Medication effectiveness cannot be considered separately from tolerability.

A medication may reduce ADHD symptoms but still represent poor treatment for an individual if adverse effects are unacceptable.

The study also highlights the limitations of the evidence base, particularly regarding longer-term outcomes, which reinforces the importance of continued clinical monitoring after medication has been initiated.

European Consensus Guidance

Kooij et al.

Kooij JJS, Bijlenga D, Salerno L, et al.

Updated European Consensus Statement on Diagnosis and Treatment of Adult ADHD.

European Psychiatry. 2019;56:14–34.

This is useful supplementary reading for clinicians treating adults.

It places pharmacological treatment within the broader management of adult ADHD and discusses:

• assessment

• comorbidity

• pharmacological treatment

• psychoeducation

• multimodal treatment

• monitoring

• functional outcomes

It is particularly useful for understanding that successful medication treatment should be judged in the context of the patient's overall functioning rather than solely through symptom scores.

World Federation of ADHD International Consensus Statement

Faraone et al.

Faraone SV, Banaschewski T, Coghill D, et al.

The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions About the Disorder.

Neuroscience & Biobehavioral Reviews. 2021;128:789–818.

This paper provides a broad evidence-based overview of ADHD and its treatment.

It is useful background reading when discussing medication with patients who have concerns about:

• whether ADHD medication is evidence-based

• stimulant treatment

• effectiveness

• safety

• long-term treatment

• common misconceptions about pharmacological management

It is particularly helpful for clinicians who want to communicate the evidence base confidently without overstating what medication can achieve.

Reading on Treatment Optimisation

A recurring theme across modern ADHD guidelines is that prescribing should aim for optimisation rather than simple medication exposure.

Treatment should not be considered successful merely because:

the patient is taking medication

or

the dose has been increased.

Instead, clinicians should look for:

reduced ADHD symptoms

plus

meaningful functional improvement

with

acceptable adverse effects.

NICE explicitly defines dose optimisation in terms of reduced symptoms, positive behavioural change and improvement in areas including education, employment and relationships while maintaining tolerable adverse effects.

CADDRA similarly emphasises titration towards treatment goals and describes the optimal dose as the point beyond which further dose increases do not produce additional improvement.

This concept is central to good ADHD prescribing.

Recommended Reading Priorities

For clinicians with limited time, I would prioritise the reading in the following order.

1. NICE NG87

Read the sections on baseline assessment, medication initiation, dose titration and monitoring carefully. These provide the foundation for UK practice.

2. BNF or BNF for Children

Use these during actual prescribing to confirm doses, contraindications, cautions, interactions and monitoring.

3. The SmPC for the medication being prescribed

Particularly important for administration instructions and formulation-specific considerations.

4. CADDRA Canadian ADHD Practice Guidelines

Excellent practical supplementary reading on titration, treatment targets and monitoring.

5. Australian Evidence-Based Clinical Practice Guideline for ADHD

Useful for broader clinical reasoning around medication initiation and individualisation.

6. Cortese et al. (2018)

Important for understanding the comparative evidence for ADHD pharmacotherapy and the need to consider efficacy alongside tolerability.

7. Kooij et al. European Consensus Statement

Particularly useful for clinicians treating adults.

8. Faraone et al. International Consensus Statement

Useful for consolidating the wider evidence base and addressing common concerns and misconceptions about ADHD medication.

Putting the Reading Into Practice

When reading these resources, avoid simply memorising medication doses.

Instead, look for answers to practical prescribing questions:

What must I establish before the first prescription?

What requires further investigation before treatment?

What should I measure at baseline?

How should I explain treatment to the patient?

How should the medication be titrated?

What should I monitor after each dose change?

How do I decide whether to increase, maintain, reduce or change treatment?

What requires slower titration or closer monitoring?

When should I stop and reassess?

These are the questions that turn prescribing guidance into clinical practice.

Final Reading Message

The central message across the major clinical guidelines is that starting ADHD medication is not a single prescribing event.

It is a process:

Assess

↓

Establish baseline

↓

Agree treatment targets

↓

Educate

↓

Start

↓

Titrate

↓

Monitor

↓

Optimise

The BNF and SmPC tell you how the medication can be prescribed.

NICE tells you how treatment should be initiated and monitored within UK clinical practice.

International guidelines provide additional perspectives on how treatment can be individualised and optimised.

Research evidence tells us what medications can achieve at a population level.

The clinician's task is to bring these sources together and determine whether treatment is producing meaningful benefit for the individual patient without unacceptable harm.

7. Knowledge Check

The following questions are designed to test practical clinical reasoning when initiating ADHD medication. Select the single best answer for each question.

Question 1

A 28-year-old man with recently diagnosed ADHD has agreed to start stimulant medication. He has no known significant physical-health problems and takes no regular medication.

Which of the following represents the most appropriate approach before issuing the first prescription?

A. Start treatment immediately because the ADHD diagnosis has already been established.
B. Arrange a routine ECG in every case before considering medication.
C. Complete an appropriate baseline assessment, including relevant physical and psychiatric history, current medication, substance-use considerations, cardiovascular assessment and baseline physical observations.
D. Start medication and obtain baseline observations at the first follow-up appointment.

Correct Answer: C

Explanation

A. Incorrect. Establishing the ADHD diagnosis does not complete the pre-treatment assessment. The clinician still needs to determine whether the proposed medication can be started safely and establish the baseline against which subsequent treatment effects will be interpreted.

B. Incorrect. A routine ECG is not required before ADHD medication in every patient. Further cardiac investigation should be guided by relevant history, examination, concomitant medication and other clinical indications.

C. Correct. Medication initiation should follow an appropriate baseline assessment. This includes consideration of physical and mental health, current medication, substance misuse and diversion risk where relevant, cardiovascular history, pulse, blood pressure, weight and height where appropriate.

D. Incorrect. Obtaining observations only after treatment begins removes an important reference point. If pulse, blood pressure or weight subsequently changes, it may be difficult to determine how much of that change occurred after medication was introduced.

The key principle is:

Establish the baseline before introducing the intervention.

Question 2

A 35-year-old woman is about to start ADHD medication. When asked what she hopes treatment will achieve, she replies:

"I just want my ADHD to be better."

What is the most useful next step?

A. Accept this as a sufficiently precise treatment target.
B. Agree specific symptom and functional targets before starting medication.
C. Explain that treatment targets are unnecessary because medication response can be determined from the dose.
D. Use improvement in a rating-scale score as the only measure of success.

Correct Answer: B

Explanation

A. Incorrect. Wanting ADHD to be "better" is understandable but too broad to provide a useful framework for titration.

B. Correct. Treatment targets should identify meaningful changes the clinician and patient can subsequently evaluate. Examples might include completing reports more consistently, interrupting less during meetings, missing fewer deadlines or managing household routines more effectively.

C. Incorrect. Dose tells you how much medication the patient is taking. It does not tell you whether treatment is effective.

D. Incorrect. Rating scales can support assessment but should not replace evaluation of real-world functioning.

Before prescribing, ask:

"If this treatment works, what should actually be different in your day-to-day life?"

Question 3

A 30-year-old starts a low initial dose of stimulant medication. After taking it for two days, he contacts the clinic and says:

"I can't feel anything. I think I should double the dose tomorrow."

What is the most appropriate response?

A. Advise him to double the dose because an effective stimulant should always be immediately noticeable.
B. Advise him to stop because lack of subjective effect demonstrates treatment failure.
C. Reinforce the agreed titration plan and explain that subjective sensation is not the sole measure of treatment response.
D. Explain that failure to notice the medication suggests the ADHD diagnosis is incorrect.

Correct Answer: C

Explanation

A. Incorrect. Patients should not independently increase medication according to whether they can "feel" it. Dose changes should follow the agreed titration plan.

B. Incorrect. A low starting dose may deliberately be conservative. Lack of obvious subjective effect does not establish medication failure.

C. Correct. The patient should continue according to the agreed plan unless there is a clinical reason to change it. Treatment response should be evaluated through changes in ADHD symptoms, functioning, duration of effect and tolerability rather than simply whether the medication produces a noticeable sensation.

D. Incorrect. Medication response is not a diagnostic test for ADHD.

The starting dose is usually the beginning of titration, not a challenge test for the diagnosis.

Question 4

A 9-year-old is starting Methylphenidate. Before treatment, his parents report that he has always been a selective eater and frequently eats very little at lunchtime.

Why is documenting this information before treatment particularly important?

A. Because pre-existing appetite difficulties automatically contraindicate stimulant medication.
B. Because any subsequent appetite reduction can then be interpreted against an established baseline.
C. Because appetite is unrelated to ADHD medication and does not need further monitoring.
D. Because the child should automatically receive a non-stimulant instead.

Correct Answer: B

Explanation

A. Incorrect. Pre-existing eating or appetite difficulties do not automatically prohibit stimulant treatment, although they may influence the risk-benefit assessment and monitoring.

B. Correct. Appetite suppression is a recognised potential adverse effect of stimulant treatment. If the child's baseline eating pattern, weight and growth are documented, subsequent changes can be assessed more accurately.

C. Incorrect. Appetite, weight and growth are important considerations during treatment, particularly in children and young people.

D. Incorrect. A non-stimulant should not automatically be selected solely because a child is a selective eater. The overall clinical circumstances should determine treatment.

The broader principle is:

If something might change during treatment, understand what it looked like before treatment.

Question 5

A 17-year-old with ADHD is being considered for stimulant medication. He has no known cardiac disease but reports that he recently fainted while playing football and has experienced episodes of rapid palpitations during exercise.

What is the most appropriate approach?

A. Start medication because most young people with ADHD do not have cardiovascular disease.
B. Start at half the usual dose without further assessment.
C. Recognise the cardiovascular history as potentially significant and undertake appropriate further assessment before routine initiation.
D. Permanently exclude all ADHD medication.

Correct Answer: C

Explanation

A. Incorrect. Population-level reassurance does not remove the need to assess clinically significant symptoms in an individual patient.

B. Incorrect. Simply reducing the starting dose does not address potentially important unexplained cardiovascular symptoms.

C. Correct. Exertional syncope and significant exertional palpitations warrant appropriate assessment before routine initiation of ADHD medication. Further cardiovascular evaluation or specialist advice may be required depending on the circumstances.

D. Incorrect. The presence of concerning symptoms indicates a need for assessment. It does not, by itself, establish that all ADHD medication will be permanently contraindicated.

The correct approach is neither to ignore cardiovascular risk nor to over-investigate every patient.

It is to investigate according to clinical indication.

Question 6

A 42-year-old woman is starting ADHD medication. She has normal cardiovascular history and examination, normal pulse and blood pressure, and takes no medication associated with additional cardiac risk.

Which statement about ECG assessment is most accurate?

A. Every adult requires an ECG before stimulant treatment.
B. Every patient requires both an ECG and echocardiogram before treatment.
C. Routine ECG assessment is not required in every patient when there is no clinical indication for it.
D. Cardiovascular assessment is unnecessary if an ECG is normal.

Correct Answer: C

Explanation

A. Incorrect. Routine ECG screening is not required for every adult simply because stimulant medication is being considered.

B. Incorrect. Routine echocardiography is also not part of standard baseline assessment for every patient.

C. Correct. Cardiovascular investigations should be guided by clinical indication. Relevant history, examination, blood pressure, pulse, coexisting conditions and concomitant medication determine whether additional assessment is necessary.

D. Incorrect. An ECG does not replace a cardiovascular history and appropriate clinical assessment.

A useful principle is:

Do not substitute indiscriminate investigation for good clinical assessment.

Question 7

A 31-year-old starts ADHD medication. At follow-up, her attention and occupational functioning have improved substantially. She is experiencing no significant adverse effects.

Her dose remains well below the maximum permitted dose.

What is the best approach?

A. Continue increasing until the maximum dose is reached.
B. Continue increasing because absence of adverse effects indicates undertreatment.
C. Consider maintaining the current dose if meaningful benefit has been achieved and the benefit-tolerability balance is good.
D. Stop treatment because effective doses should normally be close to the maximum.

Correct Answer: C

Explanation

A. Incorrect. The maximum dose is a prescribing boundary, not a therapeutic target.

B. Incorrect. Absence of adverse effects does not itself create a reason to increase medication.

C. Correct. Titration should aim for dose optimisation. If clinically meaningful symptom and functional improvement has been achieved with acceptable tolerability, further escalation may offer no advantage.

D. Incorrect. Patients vary considerably in their optimal dose.

The objective is:

optimal benefit with acceptable adverse effects

rather than:

highest possible dose.

Question 8

A 14-year-old starts stimulant medication. Two weeks later his parents report that he has become irritable.

Which question is most useful in determining whether the irritability is medication-related?

A. "Does the medication information leaflet mention irritability?"
B. "Exactly when does the irritability occur in relation to the dose and the medication wearing off?"
C. "Do you want to stop the medication immediately?"
D. "Has anyone else with ADHD experienced irritability?"

Correct Answer: B

Explanation

A. Incorrect. Knowing that an effect can occur does not establish that the medication caused it in this particular patient.

B. Correct. Timing is extremely informative. Irritability during peak medication effect may have a different interpretation from irritability occurring consistently as medication wears off. Baseline irritability should also be reviewed.

C. Incorrect. Immediate discontinuation may sometimes be appropriate for significant adverse effects, but the first task in a non-urgent situation is to understand what is happening.

D. Incorrect. Other patients' experiences do not establish causality in this patient.

When evaluating a possible adverse effect, ask:

Was it present before treatment?

When did it begin?

When does it occur relative to medication?

Did it change with dose?

How severe is it?

This is much more useful than simply asking whether the symptom appears on an adverse-effect list.

Question 9

A 22-year-old university student is starting a prescribed stimulant. He lives in shared accommodation and mentions that several friends have previously asked whether they could try ADHD medication before examinations.

What should form part of the initiation discussion?

A. Nothing additional because diversion is only relevant when the patient has a substance-use disorder.
B. Advice that sharing is acceptable provided the friend believes they have ADHD.
C. Discussion of secure storage, not sharing medication, diversion risk and the practical responsibilities associated with controlled medication.
D. Automatic refusal to prescribe any stimulant.

Correct Answer: C

Explanation

A. Incorrect. Diversion can occur in people without substance-use disorders. Environmental circumstances can substantially influence risk.

B. Incorrect. Prescribed medication should never be shared with another person. The other individual has not undergone the necessary clinical assessment, and controlled-drug considerations also apply.

C. Correct. Safe storage and explicit advice not to share or sell medication are important components of stimulant initiation, particularly where medication may be accessible to others.

D. Incorrect. The presence of potential diversion risk requires assessment and management. It does not necessarily mean stimulant treatment must automatically be refused.

Good controlled-drug prescribing includes thinking about what happens to the medication after it leaves the pharmacy.

Question 10

Which of the following best represents high-quality initiation of ADHD medication?

A. Issue the prescription, advise the patient to see how they feel and arrange review if they experience problems.
B. Complete an appropriate baseline assessment, establish functional treatment targets, explain administration and expectations, discuss relevant adverse effects and safety-netting, provide a clear titration plan and arrange monitoring and follow-up.
C. Start at the highest tolerated dose so that treatment response can be established quickly.
D. Ask the patient to adjust the dose themselves according to how productive they feel.

Correct Answer: B

Explanation

A. Incorrect. "See how you get on" is not an adequate medication-initiation strategy. It leaves treatment targets, titration, monitoring and safety-netting insufficiently defined.

B. Correct. Good initiation is a structured clinical process. The clinician establishes safety and baseline information, agrees what treatment is intended to achieve, educates the patient, starts medication appropriately and creates a plan for learning from the subsequent response.

C. Incorrect. Treatment should generally be initiated and titrated according to medication-specific prescribing guidance and individual clinical circumstances. Rapid escalation can increase adverse effects and make treatment more difficult to interpret.

D. Incorrect. Patients should not independently alter doses according to perceived productivity or subjective medication effect.

The central principle is:

The first prescription should begin a measurable and safely monitored treatment plan.

Knowledge Check Summary

Starting ADHD medication requires much more than selecting an appropriate starting dose.

Before treatment begins, clinicians should establish an appropriate baseline, including relevant physical and psychiatric information, current medication, substance-use considerations, cardiovascular assessment and physical observations.

Further cardiovascular investigation should be clinically indicated rather than routine. A normal ECG does not replace a cardiovascular history, and every patient does not require an ECG simply because ADHD medication is being considered.

Treatment targets should be agreed before medication begins.

Ask:

"If treatment works, what should actually improve?"

Successful treatment should then be judged through both symptom reduction and meaningful functional change.

Patients should understand that a starting dose is not necessarily the final therapeutic dose and that medication response does not confirm or refute the ADHD diagnosis.

Titration should aim for:

meaningful clinical benefit

improved functioning

acceptable tolerability.

The maximum permitted dose is not the treatment target.

Adverse effects should be interpreted clinically. Establish whether the symptom existed before treatment, when it appeared, whether it is related to dose or medication timing and how clinically significant it is.

Practical prescribing also matters. Patients should understand how and when medication should be taken, and medication-specific instructions should be checked against current authoritative prescribing information.

Where controlled stimulant medication is prescribed, safe storage, non-sharing and diversion risk should be considered.

The first review should be planned at initiation rather than left to chance.

At follow-up, establish:

what medication was actually taken

what improved

what changed functionally

what adverse effects occurred

what relevant physical observations show

and

whether treatment should be maintained, titrated, reduced, changed or reassessed.

The central lesson is:

Do not simply issue the first prescription. Establish the baseline, define the target, explain the treatment, start appropriately, monitor systematically and plan the next decision.